Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06563596 · ClinicalTrials.gov registry record · Phase 2
Epco, Zanu, Ritux for R/R FL or MZL
A Phase 2 study of Lymphoma and Non-Hodgkin Lymphoma, sponsored by Reid Merryman, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 3
- Study locations
NCT06563596: Recruiting Phase 2 study of Lymphoma and Non-Hodgkin Lymphoma, sponsored by Reid Merryman, MD.
NCT06563596 is a Phase 2 study of Lymphoma and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Reid Merryman, MD. The registered enrollment target is 45 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06563596, a Phase 2 study of Lymphoma and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Reid Merryman, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)
Primary Outcome
CMR rate is defined as the proportion of participants who achieved CMR during study. CMR assessed by PET/CT is defined using Lugano criteria.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Epcoritamab
- DRUG Rituximab
Study Locations (3)
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2030-03-01 |
| Phase | Phase 2 |
What NCT06563596 shows while recruiting
NCT06563596 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (91% lower).
The record links to 6 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Zanubrutinib is the first listed.
NCT06563596 reports a single indexed study location in Massachusetts, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT06563596 about?
NCT06563596 is a clinical study titled "Epco, Zanu, Ritux for R/R FL or MZL". The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research stud...
What is the current status of trial NCT06563596?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-01-21. Estimated completion is 2030-03-01.
What conditions does trial NCT06563596 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Refractory Lymphoma.
What interventions are being tested in trial NCT06563596?
The interventions under investigation include: Zanubrutinib (DRUG), Epcoritamab (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT06563596?
This trial is sponsored by Reid Merryman, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06563596 being conducted?
This trial has 3 study locations across Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06563596's enrollment target sits among peer trials
45 163rd of 299 higher than 134 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI